New MRI technique may help personalize treatment for childhood eye cancer

NCT ID NCT03267459

Recruiting now Knowledge-focused Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a special type of MRI scan can predict how children with retinoblastoma, a rare eye cancer, will respond to chemotherapy delivered directly to the eye. Researchers will scan 60 children before treatment and check if the scan results match their response 18 months later. The goal is to find early signs that could guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dynamic contrast-enhanced MRI
What this could lead to: If successful, this could help doctors identify early which children will benefit from intra-arterial chemotherapy, allowing for more personalized treatment plans.
What could go wrong: This is an early-stage observational study with only 60 participants, so results may not apply to all children. The MRI technique may not reliably predict outcomes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINOBLASTOMA

Contacts and locations

Locations

Fondation A De Rothschild
RECRUITING

Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.